Protein tyrosine phosphatase alpha (PTPa/PTPRA) was shown previously to be overexpressed in human primary breast cancers, and to suppress apoptosis in estrogen receptor-negative breast cancer cells in vitro. However, it is not known whether PTPa is important for mammary tumor initiation, maintenance and/or progression. We have used a combination of three-dimensional cultures, a transgenic mouse model of breast cancer lacking PTPa as well as xenografts of human breast cancer cell lines to address these questions. We found that PTPa knockdown after overt tumor development reduced the growth of HER2-positive human breast cancer cell lines, and that this effect was accompanied by a reduction in AKT phosphorylation. However, PTPa knockdown did not affect invasiveness of HER2-positive human breast cancer cells grown in three-dimensional cultures. Moreover, in MMTV-NeuNT/ PTPa À / À mice, PTPa ablation did not affect NeuNT-evoked tumor onset or metastasis but decreased the number of tumors per mouse. Thus, we demonstrate that PTPa contributes to both HER2/Neu-mediated mammary tumor initiation and maintenance. Our results suggest that inhibition of PTPa can have a beneficial effect on HER2-positive breast cancers, but that inhibition of additional targets is needed to block breast tumorigenesis.
INTRODUCTION
Breast cancer, which is the most frequent malignancy among women worldwide, is a heterogeneous group of diseases characterized by the activation of diverse signaling networks. 1, 2 Most of these signaling networks are regulated by tyrosine phosphorylation, which is balanced by the opposing actions of protein tyrosine kinases (PTKs) and protein tyrosine phosphatases (PTPs). 3 Although PTKs have been studied extensively in breast cancer and other fields, PTPs have been associated only recently with key signaling events orchestrating breast tumor initiation, progression and metastasis. PTPs can have either tumor promoting or suppressing roles in breast cancer. [4] [5] [6] [7] [8] [9] [10] The receptor-like PTPa (encoded by PTPRA) was shown previously to be highly expressed in a subset (B29%) of low tumor grade and estrogen receptor (ER)-positive human primary breast tumors. 11 In addition, PTPa knockdown was shown to induce apoptosis in ER-negative breast cancer cells but not in immortalized non-tumorigenic breast cells. 12 Mechanistically, PTPa acts as a Src family kinase activator via dephosphorylation of the Src-inhibitory tyrosine 527. 13, 14 However, the prototype of the PTP family, PTP1B, is active in breast cancer and may be a major Src activator in several human breast cancer cell lines. [15] [16] [17] Thus, multiple PTPs seem to participate in the activation of Srcsignaling cascades and potentially in other pathways.
In the present study, we used a combination of mouse genetics, conditional reverse genetics and three-dimensional cultures to examine the role of PTPa in the initiation, invasion, maintenance and metastasis of breast tumors belonging to the ErbB2 (HER2)-positive subtype.
RESULTS AND DISCUSSION
To determine whether PTPa expression is important for mammary tumor onset, we crossed PTPa þ / þ or PTPa À / À mice 18 to MMTVNeuNT animals expressing the activated HER2/Neu oncogene, NeuNT, in mammary epithelial cells. We then compared tumor onset in PTPa þ / þ -MMTV-NeuNT and PTPa À / À -MMTV-NeuNT mice. The number of tumors per mouse was lower in PTPa À / À -MMTV-NeuNT than in PTPa þ / þ -MMTV-NeuNT mice (Figure 1a ), but no significant differences in tumor volume were observed (Figure 1b (miRs) targeting PTPa. To exclude off-target effects, two different miRs (PTPa miR1 and PTPa miR2) were used for targeting the PTPa transcript at different locations (knockdown level is shown in Figure 4c ). We then seeded a single cell suspension of MCF10A-NeuNT cells expressing inducible control (CTRL) miR, PTPa miR1 or PTPa miR2 in three-dimensional cultures and activated miR expression with dox. Surprisingly, there was no major effect on invasion upon PTPa knockdown in MCF10A-NeuNT cells (Figure 3a) .
The PTPa þ / þ -MMTV-NeuNT and PTPa À / À -MMTV-NeuNT mice were also used to investigate the consequences of PTPa deletion in mammary tumors on the formation of lung metastases in vivo. Lung metastases were found in three out of five mice of the PTPa þ / þ -MMTV-NeuNT group, and two out of four mice in the PTPa À / À -MMTV-NeuNT group (Figure 3b ). However, there was no difference in the average number of metastatic foci per animal between the PTPa þ / þ -MMTV-NeuNT and PTPa À / À -MMTVNeuNT groups (Figure 3c ). Thus, PTPa appears not to be involved in the invasive and metastatic process of HER2/NeuNT-positive mammary tumors, although we cannot completely rule out a potential role of PTPa in metastasis.
Despite the fact that PTPa is overexpressed in a large subset of primary breast tumors, 11 the role of PTPa in breast tumor maintenance has not been examined. To address this question, we injected two HER2-positive human breast cancer cell lines (MCF10A-NeuNT and BT474) expressing inducible CTRL or PTPa miRs into the mammary fat pad of immunodeficient mice, and administered dox to achieve PTPa knockdown once tumors became palpable. Interestingly, PTPa depletion after tumor onset decreased the growth of both MCF10A-NeuNT and BT474 xenografts (Figures 4a and b) . We then analyzed PTPa expression and the activation of the Erk and Akt pathways upon PTPa knockdown in vivo. Along with the downregulation of the PTPa protein we observed a decrease in Akt phosphorylation (Ser473) but no consistent change in Erk phosphorylation in MCF10A-NeuNT and BT474 tumors (Figure 4c) . These results suggest a role for PTPa in the maintenance of breast tumors of the HER2-positive subtype.
In summary, our investigations have identified PTPa as a positive mediator of tumor maintenance in HER2-positive breast tumors. Moreover, PTPa depletion upon tumor development is accompanied by a reduction in Akt phosphorylation, highlighting the impact of PTPa on the PI3K pathway, which has not been linked previously to this tyrosine phosphatase. Interestingly, PTPa whole-body knockout decreased the number of NeuNT-evoked tumors per mouse. Thus, this phosphatase may also be involved in the tumor initiation process. However, no differences in tumor latency, tumor volume or metastasis were observed between PTPa þ / þ -MMTV-NeuNT and PTPa À / À -MMTV-NeuNT animals, suggesting that compensatory pathways may overcome the effect of PTPa knockout in the MMTV-NeuNT transgenic mice. For example, the structurally related PTPe was previously shown to be oncogenic in Neu-mediated carcinogenesis. 19 Therefore, PTPe or other tumor promoting PTPs (for example, SHP2 and PTP1B) may be part of similar tumorigenic pathways and, thus, inhibition of multiple PTPs may be needed to abrogate tumorigenesis of HER2-positive breast cancer. 
